Skip to content
RDL
Network
Ecosystem
Switch app
TR
About
FAQ
Sign in
Get started
Challenges in meta-analysis of randomized clinical trials for rare harmful cardiovascular events: The case of rosiglitazone — Adrían V. Hernández (2008) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Challenges in meta-analysis of randomized clinical trials for rare harmful cardiovascular events: The case of rosiglitazone
Shared by
John P A Ioannidis
Stanford University
Challenges in meta-analysis of randomized clinical trials for rare harmful cardiovascular events: The case of rosiglitazone
Article
2008
en
Authors
+1 more
AH
Adrían V. Hernández
EW
Esteban Walker
John P A Ioannidis
Stanford University
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2014
Aspirin for Primary Prevention of Cardiovascular Events: Meta-Analysis of Randomized Controlled Trials and Subgroup Analysis by Sex and Diabetes Status
Manling Xie
,
Zhilei Shan
,
Yan Zhang
,
Sijing Chen
,
Wei Yang
,
Wei Bao
,
Rong Ying
,
Xuefeng Yu
,
Frank B Hu
,
Liegang Liu
Article
2024
Rare disease clinical trials: challenges and best practices
Giuseppe Remuzzi
Article
2017
Late thrombotic events after bioresorbable scaffold implantation: a systematic review and meta-analysis of randomized clinical trials
Carlos Collet
,
Taku Asano
,
Yosuke Miyazaki
,
Erhan Tenekecioğlu
,
Yuki Katagiri
,
Yohei Sotomi
,
Rafael Cavalcante
,
Robbert J. de Winter
,
Takeshi Kimura
,
Runlin Gao
,
Serban Puricel
,
Stéphane Cook
,
Davide Capodanno
,
Yoshinobu Onuma
,
Patrick W. Serruys
European Heart Journal
Article
1995
Meta-analysis of Randomized Controlled Trials
David Moher
Article
1996
P22 Randomized and non-randomized patients in large clinical trials: The case of GISSI
M. G. Franzosi
,
Aldo Maggioni
,
on behalf of GISSI Investigators
Discussion(0)
No comments yet. Be the first to comment.